Publications by authors named "Lumbini Azim"

Claim this Profile
C
Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial.
Michael Berger, Timea Helter, Lumbini Azim, Thomas Chadwick, Paul Courtney

J Affect Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial.
Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, Victoria Bartle, Michael Berger

Health Technol Assess· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study).
R Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, Victoria Bartle, Michael Berger

J Psychopharmacol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole/Sertraline Combination: Clinical and Cost-Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)-Protocol for a Nested Qualitative Study.
Isobel Hoppe, Stuart Watson, Caroline Kemp, Fiona Turnbull, Firoza Davies, Lumbini Azim

Health Expect· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study).
Lumbini Azim, Paul Hindmarch, Georgiana Browne, Thomas Chadwick, Emily Clare

BMC Psychiatry· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis